AQST
Price
$2.79
Change
+$0.03 (+1.09%)
Updated
May 9, 02:46 PM (EDT)
Capitalization
383.26M
3 days until earnings call
TLRY
Price
$0.43
Change
-$0.01 (-2.27%)
Updated
May 9, 12:54 PM (EDT)
Capitalization
1.87B
75 days until earnings call
Ad is loading...

AQST vs TLRY

Header iconAQST vs TLRY Comparison
Open Charts AQST vs TLRYBanner chart's image
Aquestive Therapeutics
Price$2.79
Change+$0.03 (+1.09%)
Volume$1.2K
Capitalization383.26M
Tilray Brands
Price$0.43
Change-$0.01 (-2.27%)
Volume$8.69K
Capitalization1.87B
AQST vs TLRY Comparison Chart
Loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. TLRY commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Hold and TLRY is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (AQST: $2.76 vs. TLRY: $0.44)
Brand notoriety: AQST: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AQST: 75% vs. TLRY: 76%
Market capitalization -- AQST: $383.26M vs. TLRY: $1.87B
AQST [@Pharmaceuticals: Other] is valued at $383.26M. TLRY’s [@Pharmaceuticals: Other] market capitalization is $1.87B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, AQST is a better buy in the long-term than TLRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 6 TA indicator(s) are bullish while TLRY’s TA Score has 5 bullish TA indicator(s).

  • AQST’s TA Score: 6 bullish, 3 bearish.
  • TLRY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, AQST is a better buy in the short-term than TLRY.

Price Growth

AQST (@Pharmaceuticals: Other) experienced а -8.00% price change this week, while TLRY (@Pharmaceuticals: Other) price change was -8.90% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.67%. For the same industry, the average monthly price growth was +11.45%, and the average quarterly price growth was +11.21%.

Reported Earning Dates

AQST is expected to report earnings on Aug 12, 2025.

TLRY is expected to report earnings on Jul 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.67% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.87B) has a higher market cap than AQST($383M). AQST YTD gains are higher at: -22.472 vs. TLRY (-66.744). AQST has higher annual earnings (EBITDA): 1.18M vs. TLRY (-1.23B). TLRY has more cash in the bank: 260M vs. AQST (23.9M). AQST has less debt than TLRY: AQST (33.3M) vs TLRY (529M). TLRY has higher revenues than AQST: TLRY (700M) vs AQST (50.6M).
AQSTTLRYAQST / TLRY
Capitalization383M1.87B21%
EBITDA1.18M-1.23B-0%
Gain YTD-22.472-66.74434%
P/E RatioN/A8.52-
Revenue50.6M700M7%
Total Cash23.9M260M9%
Total Debt33.3M529M6%
FUNDAMENTALS RATINGS
AQST vs TLRY: Fundamental Ratings
AQST
TLRY
OUTLOOK RATING
1..100
293
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
6296
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (35) in the Pharmaceuticals Major industry is in the same range as TLRY (49) in the Biotechnology industry. This means that AQST’s stock grew similarly to TLRY’s over the last 12 months.

AQST's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as TLRY (100) in the Biotechnology industry. This means that AQST’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's SMR Rating (93) in the Biotechnology industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew similarly to AQST’s over the last 12 months.

AQST's Price Growth Rating (62) in the Pharmaceuticals Major industry is somewhat better than the same rating for TLRY (96) in the Biotechnology industry. This means that AQST’s stock grew somewhat faster than TLRY’s over the last 12 months.

TLRY's P/E Growth Rating (95) in the Biotechnology industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew similarly to AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTTLRY
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JVTNX80.931.42
+1.79%
Janus Henderson Venture N
DFQTX37.020.33
+0.90%
DFA US Core Equity 2 I
FOBAX19.470.06
+0.31%
Tributary Balanced Instl
WCMSX22.36N/A
N/A
WCM International Small Cap Growth Instl
VCRIX14.06-0.15
-1.06%
NYLI CBRE Global Infrastructure Class I